Table 3: The incidence of hepatotoxicity caused by EGFR-TKIs.

Study nameIncidence of hepatotoxicity
Any grade
Grade 3, 4Ratio of patients with  EGFR gene mutation Ethnicity/raceNumber of patients who administrate EGFR-TKIs References

Gefitinib

V15-3224.2%11.1%54.%Japanese244Maruyama et al. [13]
IPASS9.4%21.7%Asian607Mok et al. [14]
NEJ00255.3%26.3%100%Japanese114Maemondo et al. [5]
WJTOG340570.1%24%Japanese177Mitsudomi et al. [6]

Erlotinib

Phase II study in Japan24.2%3.2%Not describedJapanese62Kubota et al. [20]
OLCSG trial 070530%0%0%Japanese30Yoshioka et al. [21]
Trust<1%<1%Not describedWhite, Asian, Black6580Reck et al. [22]

Abbreviations: EGFR: epidermal growth factor receptor; TKIs: tyrosine kinase inhibitors.